ICD-10-PCS FY2020 (August) code changes

Historical release · ICD-10-PCS FY2020 (August) · Effective August 1, 2020 – September 30, 2020 ICD-10-PCS FY2027 is the release in force (effective October 1, 2026).

Part of FY2020 coding changes

Every recorded ICD-10-PCS code addition, deletion, description revision, billable-status change and tabular-instruction change for FY2020 (August), effective August 1, 2020.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

Release: ICD-10-PCS FY2020 (August)
Effective: August 1, 2020
Code set period: 2020-08-01 through 2020-09-30

FY2020 (August) at a glance

12Added12 of them valid for submission

Explore the complete recorded change list →

Compare a code

Enter any ICD-10-PCS code to see what this release does to it: added, deleted, description revised, billable status changed, new child codes, or no change at all. The answer is a lookup against the recorded changes below — nothing is generated.

The full recorded change list

Every recorded change, grouped by what kind of change it is. Each entry shows the code's own description first; tabular instructions and relationship text are labeled separately beneath it.

Added to the code set (12)

XW013F5 — Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5
XW033E5 — Introduction of Remdesivir Anti-infective into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033F5 — Introduction of Other New Technology Therapeutic Substance into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033G5 — Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW033H5 — Introduction of Tocilizumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW043E5 — Introduction of Remdesivir Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 5
XW043F5 — Introduction of Other New Technology Therapeutic Substance into Central Vein, Percutaneous Approach, New Technology Group 5
XW043G5 — Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW043H5 — Introduction of Tocilizumab into Central Vein, Percutaneous Approach, New Technology Group 5
XW0DXF5 — Introduction of Other New Technology Therapeutic Substance into Mouth and Pharynx, External Approach, New Technology Group 5
XW13325 — Transfusion of Convalescent Plasma (Nonautologous) into Peripheral Vein, Percutaneous Approach, New Technology Group 5
XW14325 — Transfusion of Convalescent Plasma (Nonautologous) into Central Vein, Percutaneous Approach, New Technology Group 5

Sources

Official source data

Publisher: Centers for Medicare & Medicaid Services (CMS) and the National Center for Health Statistics (CDC/NCHS)
Release: ICD-10-PCS FY2020 (August)
Source file: 2020-covid-19-update-files-effective-august-1-2020.zip
File checksum (SHA-256): 9e5c07f195b62823c93d7aaafa18f83b76fc51b1f381a99b75f6eebc7522fc15
Rebuilt snapshot: CMS published this update as addenda only, with no full code file. The snapshot compared here is the FY2020 code file plus the 12 codes in CMS's August 1, 2020 addenda.
Data type: Public domain code descriptions and tabular instructions. No licensed content.

MedCoder-derived analysis

Change detection: Every addition, deletion, description revision, billable-status change and tabular-instruction change on this page is computed by diffing the two code-description files above, line by line.
Editorial analysis: The grouping of changes into themes, the successor determinations and the coder-impact notes are written by MedCoder against those files. They are not CMS statements.
Independence: MedCoder is an independent coding reference built on public federal data. It is not affiliated with, endorsed by or certified by CMS, and it is not an official CMS coding tool.

Continue

All releases in the Change Ledger